[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastatic-lobular-breast-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastatic-lobular-breast-carcinoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100594542","phase-1-68gaga-dota-5g-as-a-diagnostic-imaging-agent-for-metastaticadvanced-invasive-lobular-breast-cancer-lbc-100594542",false,"NCT07020806","[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic\u002FAdvanced Invasive Lobular Breast Cancer (LBC)","Inclusion Criteria:\n\n* (Ability to understand and willingness to sign a written informed consent document.\n* Men and women age ≥ 18 yrs\n* Confirmed presence of metastatic\u002Fadvanced invasive lobular breast cancer and measurable disease per RECIST (version 1.1) or PERCIST\n* Available archival tumor tissue\n* Eastern Cooperative Oncology Group Performance Status ≤ 2\n* Hematologic parameters defined as: Absolute neutrophil count (ANC) ≥ 1000 cells\u002Fmm3,Platelet count ≥ 100,000\u002Fmm3, Hemoglobin ≥ 8 g\u002FdL.\n* Blood chemistry levels defined as: AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN), Total bilirubin ≤ 2 times ULN, eGFR \\>60 mL\u002Fmin\u002F1.73m\\*2\n* Anticipated life expectancy ≥ 3 months\n* Able to remain motionless for up to 30-60 minutes per scan.\n\nExclusion Criteria:\n\n* Pregnant and lactating women\n* Prisoners\n* Concurrent malignancy of a different histology that could confound imaging interpretation.\n* Patients who cannot undergo PET\u002FCT scanning because of weight limits(\\>350lbs)","ALL","18 Years","89 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a prospective study using \\[68Ga\\]Ga DOTA-5G PET\u002FCT imaging in patients diagnosed with metastatic\u002Fadvanced invasive lobular breast cancer (LBC).",[26],"Metastatic Lobular Breast Carcinoma","RECRUITING","2026-09-09",{"date":30,"type":31},"2026-09-14","ACTUAL",{"date":33,"type":31},"2025-11-18",{"date":35,"type":20},"2027-06",{"name":37,"class":38},"University of California, Davis","OTHER"]